Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

20.10 -1.50 (-6.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 592,173
Open 19.26
Bid (Size) 18.00 (200)
Ask (Size) 21.20 (300)
Prev. Close 21.60
Today's Range 17.89 - 21.12
52wk Range 5.550 - 29.27
Shares Outstanding 25,676,798
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
From Nuvectis Pharma, Inc.
Via GlobeNewswire

Performance

YTD
+136.2%
+136.2%
1 Month
+2.4%
+2.4%
3 Month
+126.1%
+126.1%
6 Month
+140.4%
+140.4%
1 Year
+175.7%
+175.7%

More News

Read More
InvestorNewsBreaks – Nuvectis Pharma, Inc. (NASDAQ: NVCT) Prices $100 Million Public Offering
Via Investor Brand Network
News headline image
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
Via Newsfile
Here are the top movers in Tuesday's session. ↗
Via Chartmill
Top movers analysis in the middle of the day on 2026-06-30: top gainers and losers in today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Tuesday's session. ↗
Via Chartmill
Tuesday's pre-market session: top gainers and losers ↗
Via Chartmill
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Via Chartmill
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. To Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including the Combination with Osimertinib in NSCLC
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
News headline image
Nuvectis (NVCT) Q2 Loss Widens 43% ↗
Via The Motley Fool
News headline image
Discover the top movers in Thursday's pre-market session. ↗
Via Chartmill

Frequently Asked Questions

Is Nuvectis Pharma, Inc. - Common Stock publicly traded?
Yes, Nuvectis Pharma, Inc. - Common Stock is publicly traded.
What exchange does Nuvectis Pharma, Inc. - Common Stock trade on?
Nuvectis Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Nuvectis Pharma, Inc. - Common Stock?
The ticker symbol for Nuvectis Pharma, Inc. - Common Stock is NVCT on the Nasdaq Stock Market
What is the current price of Nuvectis Pharma, Inc. - Common Stock?
The current price of Nuvectis Pharma, Inc. - Common Stock is 20.10
When was Nuvectis Pharma, Inc. - Common Stock last traded?
The last trade of Nuvectis Pharma, Inc. - Common Stock was at 08/04/26 04:00 PM ET
What is the market capitalization of Nuvectis Pharma, Inc. - Common Stock?
The market capitalization of Nuvectis Pharma, Inc. - Common Stock is 516.10M
How many shares of Nuvectis Pharma, Inc. - Common Stock are outstanding?
Nuvectis Pharma, Inc. - Common Stock has 516M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.